CM
IBRX icon

Caption Management’s ImmunityBio IBRX Stock Holding History

Caption Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Buy
+34,000
New +$233K ﹤0.01% 1311
2025
Q1 		– Sell
-85,000
Closed -$218K – 1758
2024
Q4 		$218K Buy
+85,000
New +$354K ﹤0.01% 1263
2024
Q2 		– Sell
-266,800
Closed -$1.43M – 1316
2024
Q1 		$1.43M Buy
+266,800
New +$1.21M 0.02% 641
2023
Q2 		– Sell
-60,000
Closed -$109K – 1252
2023
Q1 		$109K Buy
+60,000
New +$187K ﹤0.01% 967

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caption Management's IBRX Position: Q1 2026 in Review

Caption Management opened a new position in ImmunityBio (IBRX) in Q1 2026: 1,000 shares worth $7.67K. The stake represents ﹤0.01% of the portfolio and ranks #1468 among its holdings. This is a return to the name: Caption Management previously reported a position in IBRX as recently as Q3 2025.

Caption Management first reported a position in IBRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $396K in Q1 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Caption Management held 1,000 shares of ImmunityBio worth $7.67K as of Q1 2026.
  • ImmunityBio was a new Caption Management position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1468 holding.
  • Caption Management first reported a position in ImmunityBio in Q1 2024 and has held it in 7 quarters since.
  • Caption Management's ImmunityBio position peaked at $396K in Q1 2024.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.